Actualités dans la physiopathologie de la sclérodermie systémique : vers de nouvelles opportunités thérapeutiques, Rev Med Interne, vol.40, pp.654-663, 2019. ,
Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies, Rheumatol (Oxford), vol.51, pp.1017-1043, 2012. ,
Systemic sclerosis: Recent insights, Joint Bone Spine, vol.82, pp.148-53, 2015. ,
Mise au point sur les sclérodermies très précoces et précoces, Rev Med Interne, vol.40, pp.517-522, 2019. ,
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database, Ann Rheum Dis, vol.69, pp.1809-1824, 2010. ,
, Protocole National de Diagnostic et de Soins, 2017.
,
, Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, J Rheumatol, vol.15, pp.202-207, 1988.
2013 classification criteria for systemic sclerosis: an American College of ,
League against Rheumatism collaborative initiative, Arthritis Rheum, vol.65, pp.2737-2784, 2013. ,
Van Doornum S. Cardiovascular disease in systemic ,
A critical view on cardiovascular risk in systemic sclerosis, Rheumatol Int, vol.37, pp.85-95, 2017. ,
Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality, Autoimmun Rev, vol.10, pp.259-66, 2011. ,
Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors, Arthritis Res Ther, vol.10, p.49, 2008. ,
A cohort study of cancer incidence in systemic sclerosis, J Rheumatol, vol.33, pp.1113-1119, 2006. ,
Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies, Arthritis Rheum, vol.65, pp.1913-1934, 2013. ,
Malignancies associated with systemic sclerosis, Autoimmun Rev, vol.11, pp.852-857, 2012. ,
Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer, Ann Rheum Dis, vol.77, pp.1179-1186, 2018. ,